Zetagen Therapeutics Raises $9.79M in Series B Funding to Advance Metastatic Cancer Treatment
Zetagen Therapeutics, a Syracuse, N.Y.-based clinical-stage biopharmaceutical company, announced today that it has raised $9.79 million in Series B funding. The round was led by New York Ventures and Consolidated Capital Investments, LLC, with participation from private investors.
The funding will be used to support the development of Zetagen’s lead pipeline asset, ZetaMet™, which is a first-in-class, targeted therapy for the treatment of metastatic breast cancer bone lesions. ZetaMet™ is currently in Phase 2a clinical trials and has the potential to provide a new treatment option for patients with metastatic breast cancer who are at risk of developing skeletal-related events (SREs), such as bone fractures and pain.
In addition to ZetaMet™, the funding will also be used to support the development of ZetaMAST™, a formulation of ZetaMet™ that is designed for intra-tumoral injection in soft tissue organs. ZetaMAST™ has the potential to treat metastatic lesions in a variety of organs, including the liver, lung, and brain.
Zetagen Therapeutics is also developing a pipeline of other oncological and osteologic treatments. These assets include Z-Pros™, a treatment for metastatic prostate cancer; ZetaMet Flowable™, a liquid formulation of ZetaMet™ for the treatment of SREs; and ZetaFuse™ and ZetaBase®, which are bone graft substitutes for the treatment of osteolytic bone disease.
The funding round is a significant milestone for Zetagen Therapeutics and will help the company accelerate the development of its pipeline of innovative cancer treatments. The company is well-positioned to make a significant impact on the treatment of metastatic cancer and osteologic conditions.
Deal Table for Zetagen Therapeutics
|Key People||Investors||Amount Invested||Sector||Funding Round|
|Joe C. Loy, CEO||New York Ventures, Consolidated Capital Investments, LLC, and private investors||$9.79 million||Healthcare||Series B|
Startups that are Breakthroughs in Metastatic Cancer Treatments
There are a number of other startups developing innovative metastatic cancer treatments. Some of these companies include:
- Atara Biotherapeutics is developing a T-cell immunotherapy for the treatment of metastatic melanoma.
- Loxo Oncology is developing a targeted therapy for the treatment of metastatic colorectal cancer.
- Teva Pharmaceutical Industries is developing a combination therapy for the treatment of metastatic breast cancer.
Recent Developments in the Metastatic Cancer Treatment Sector
A number of new companies developing innovative therapies in the Metastatic Cancer treatment sector. In recent years, there have been significant advances in the development of targeted therapies, which are designed to specifically target cancer cells. These therapies have the potential to provide more effective and less toxic treatment options for patients with metastatic cancer.
One example of a targeted therapy in development is Zetagen Therapeutics’ ZetaMet™, which is a first-in-class, targeted therapy for the treatment of metastatic breast cancer bone lesions. ZetaMet™ is currently in Phase 2a clinical trials and has the potential to provide a new treatment option for patients with metastatic breast cancer who are at risk of developing skeletal-related events (SREs), such as bone fractures and pain.
Another area of active development in the metastatic cancer treatment sector is immunotherapy. Immunotherapy therapies work by stimulating the body’s immune system to attack cancer cells. These therapies have shown promise in clinical trials, but they are still in the early stages of development.
One example of immunotherapy in development is Atara Biotherapeutics’ T-cell immunotherapy for the treatment of metastatic melanoma. This therapy uses a patient’s own T cells to attack cancer cells. Atara Biotherapeutics is currently conducting Phase 2 clinical trials of this therapy.
The development of new metastatic cancer treatments is a high priority for the cancer research community. The need for new treatments is great, as metastatic cancer is a very difficult disease to treat. The recent developments in the metastatic cancer treatment sector are a positive sign for the future of cancer care.